Correction: This article has been changed. The original version stated that Associate Professor Suzanne Nielsen chaired the TGA’s joint advisory committee on chemicals and medicine scheduling.

 This was incorrect. Professor Nielsen did not chair the committee. She was chair of the TGA’s advisory committee on medicines scheduling. Australian Doctor apologises for the error.

Patients will be able to secure low dose cannabidiol from pharmacists from next year under a TGA interim decision to down-schedule the drug. 

Cannabidiol products are classed as unapproved S4 medicines and are accessible through the watchdog’s Special Access Scheme via an application by a doctor.